TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05021575

Intervention type: OTHER
Intervention: Data collection on hospitalisation
Description: Hospitalisation data from 1 January to 30 November of the analysed year were obtained from National Health Insurance Fund under the Ministry of Health.~Data on hospitalisation were collected if any of the diagnoses (principal or secondary) were in I00-I99 range. Hospitalisation data covered hospitalisation date, patient age, sex, municipality and outcome. Data on cardiovascular procedures performed during hospitalisations included date of the procedure and ACHI (Australian Classification of Health Interventions) code.

Intervention type: OTHER
Intervention: Data collection on cardiovascular mortality
Description: Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.

Intervention type: OTHER
Intervention: Data collection on cardiovascular mortality
Description: Data on cardiovascular mortality were obtained from death certificates provided by Causes of Death Registry from Institute of Hygiene and covered the period from 1 January to 31 December of the analysed year. Death certificates were included in the study when cause of death was adjudicated to be in I00-I99 range. Date and place of death (hospital, home, other or unspecified), patient age and sex were recorded.

Intervention type: OTHER
Intervention: Data collection of patients presenting to the tertiary care centre with acute coronary syndrome
Description: Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.

Intervention type: OTHER
Intervention: Data collection of patients presenting to the tertiary care centre with acute coronary syndrome
Description: Demographic, clinical and percutaneous coronary intervention (PCI) related data were collected from 1st March to 30th June of the analysed year. The timing of the chest pain onset, call for medical help, first medical contact (FMC), arrival to PCI centre, and PCI procedure were analysed.
Study: NCT04697732

Intervention type: OTHER
Intervention: General anesthesia
Description: Following emergence from general anesthesia, patients will be evaluated at 4 different timepoints; (a) One hour after emergence, (b) Twenty four hour after emergence (c) One week after emergence (d) One month after emergence. The first interview will be made face-to-face in the recovery unit, and other interviews will be made by phone.
Study: NCT01959438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium selenite (Introselen)
Description: Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium selenite
Description: Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
Study: NCT03144986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Insula-coil rTMS
Description: Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
Study: NCT00820417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab/Gefitinib combination and/or monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab/Gefitinib combination and/or monotherapy
Study: NCT01962870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00889642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iontophoretic Drug Delivery System with Lidocaine/Epinephrine
Description: Active- 10.5% Lidocaine/0.179% Epinephrine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Iontophoretic Drug Delivery System with Epinephrine
Description: Placebo- 0.179% Epinephrine
Study: NCT00379067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin OCAS
Description: Adrenoceptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01511081

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT (stereotactic body radiotherapy)
Description: 50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBPT (stereotactic body proton therapy)
Description: 50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
Study: NCT02321345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Support
Description: Palliative care meetings Quality of Life Assessments
Study: NCT03743701

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The method of transrectal ultrasound in В-mode
Description: A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The method of transrectal ultrasound examination using three-dimensional image reconstruction.
Description: A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
Study: NCT03600532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachable Moment Brief Intervention (TMBI)
Description: Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
Study: NCT04138290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predictix Antidepressant Software tool
Description: Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
Study: NCT03073993

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: feeding tube insertion
Description: Feeding tube was inserted in hemodynamically stable babies for purpose of feeding

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: feeding tube insertion
Description: Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
Study: NCT02982941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: enoblituzumab administered IV weekly for up to 96 weeks
Study: NCT01850407

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Education Counseling
Study: NCT02072369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAEDA Glove
Description: Voice And EMG-Driven Actuated glove used during training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: novel upper extremity occupational therapy focused on the hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: novel upper extremity occupational therapy focused on the hand
Study: NCT03817268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy
Description: Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
Study: NCT02464722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia was induced with propofol 2 mg kg-1
Study: NCT01025427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir, tenofovir/emtricitabine
Description: 16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
Study: NCT02464722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia was induced with propofol 2 mg kg-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Anesthesia was induced with rocuronium 0.6 mg kg-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Anesthesia was induced with rocuronium 0.6 mg kg-1
Study: NCT05268952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Description: Blood/urine sampling and scans are done at regular intervals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scans (CT, gallium-68 DOTATE/TOC/NOC PET-CT)
Description: Scans will be done at regular intervals
Study: NCT00206713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: 6 μg/kg sargramostim administered SC once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered SC once daily during the randomized retreatment phase.
Study: NCT03382808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEE Training
Description: Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GAZE Training
Description: Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
Study: NCT02808468

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Therapy
Description: Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
Study: NCT01226576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS Treatment
Description: Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
Study: NCT04465292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildrakizumab Prefilled Syringe
Description: Patients will receive Tildrakizumab 100 mg subcutaneously at Weeks 0, 4, and 16. The study staff will administer each dose.
Study: NCT03139344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-frequency Exercise
Description: The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-frequency Exercise
Description: The quadriceps/hamstrings will perform exercise via the application of low-frequency electrical stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency Exercise
Description: The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency Exercise
Description: The quadriceps/hamstrings will perform exercise via the application of high-frequency electrical stimulation.
Study: NCT00167310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (omega-3 fatty acid)
Description: 2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
Study: NCT03188510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC
Study: NCT04254094

Intervention type: OTHER
Intervention: Neuropsychological scales
Description: Basic Activity of Daily Living (BADL) and Instrumental Activities of Daily Living (IADL), Neuropsychiatric Inventory (NPI), Cornell Scale for Depression in Dementia (CSDD), Clinical Dementia Rating Scale (CDR) and defining dementia criteria. Also as part of this study, an MRI examination at baseline and at 18 months follow-up will be performed in the Bordeaux center
Study: NCT01325805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Weight Loss Program
Description: Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Weight Loss Counseling
Description: Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
Study: NCT02083497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rigid bandage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: elastic bands

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: without the use of banding
Study: NCT04954157

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Phase-1: Breath Holding Test
Description: In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Phase-1: Breath Holding Test
Description: In this phase of the study, each subject will be asked to hold their breath for up to 60 seconds or until they can longer hold it. While they are holding their breath, subjects will be hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2: 6-Minute Walk Test (6MWT)
Description: In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Phase 2: 6-Minute Walk Test (6MWT)
Description: In this phase of the study, each subject will be asked to walk for 6 minutes in their hospital room or hallway. Their rate of perceived exertion will be measured while also hooked up to a monitor that will measure their Peripheral oxygen saturation (SpO2) respiratory rate (RR), and heart rate (HR).
Study: NCT01805557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-DHAP
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-DHAP
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-DHAP
Description: * Rituximab 375 mg/sqm iv day 0 or 1~* Bortezomib SC 1.5 mg/sqm day 1, day 4~* Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~* Dexamethasone 40 mg day 1-4~* Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~* Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days.
Study: NCT03540199

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study: NCT03052049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolization
Description: The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
Study: NCT00186901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (Tums), vitamin D
Description: Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo